Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. (Q40253260)

From Wikidata

Jump to navigation Jump to search

scientific article published on September 2006

Language	Label	Description	Also known as
English	Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.	scientific article published on September 2006

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16856892%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16856892%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

based on heuristic

inferred from title

Ingo Ringshausen

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16856892%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

author name string

Kathrin Wanner

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16856892%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Susanne Hipp

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16856892%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Madlene Oelsner

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16856892%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Christian Bogner

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16856892%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Christian Peschel

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16856892%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Thomas Decker

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16856892%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

language of work or name

0 references

publication date

1 September 2006

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16856892%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

British Journal of Haematology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16856892%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

134

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16856892%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

475-484

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16856892%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16856892%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

The TOR pathway: a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

The evolving experience using everolimus in clinical transplantation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

Evidence for cyclin D3 as a novel target of rapamycin in human T lymphocytes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

Mechanisms of resistance to rapamycins

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

Targeting mTOR signaling for cancer therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

Rapamycins: mechanism of action and cellular resistance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

Cyclin A is a functional target of retinoblastoma tumor suppressor protein-mediated cell cycle arrest

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

Lipopolysaccharide-mediated transcriptional activation of the human tissue factor gene in THP-1 monocytic cells requires both activator protein 1 and nuclear factor kappa B binding sites

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

Gefitinib and cisplatin-based chemotherapy in non-small-cell lung cancer: simply a bad combination?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

Mammalian target of rapamycin inhibition as therapy for hematologic malignancies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

Small-molecule cyclin-dependent kinase modulators

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06210.X

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40253260&oldid=1513027643"